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Abstract 37 
Context 38 
Male ageing is associated with lower circulating testosterone (T) and increased incidence of 39 
cardiovascular disease (CVD). Whether physical activity (PA) interacts with hormones to 40 
modify CVD risk is unclear. 41 
Objective 42 
We assessed whether PA and sex hormone concentrations were independently associated 43 
with measures of CVD risk. 44 
Participants 45 
1,649 men. 46 
Methods 47 
Leisure, home, work and total PA were ascertained. At baseline, serum T, 48 
dihydrotestosterone (DHT) and estradiol (E2) were assayed. Men were stratified into high 49 
PA+high hormone (H/H); low PA+high hormone (L/H); high PA+low hormone (H/L) and 50 
low PA+low hormone (L/L). 51 
Results 52 
Mean age was 49.8 years at outset with 415 CVD events and 127 CVD deaths occurring 53 
during 20-year follow-up. Men with higher PA and higher T or DHT had lower odds of 54 
metabolic syndrome (eg. leisure H/H vs L/L odds ratio [OR] 0.17 p<0.001 for T, 0.26 55 
p<0.001 for DHT). Men with higher PA and E2 had lower risk of metabolic syndrome (eg. 56 
leisure PA H/H vs L/L OR 0.51, p=0.001). Men with higher leisure, work or total PA and 57 
higher DHT had the lowest risk of CVD death (eg. leisure H/H HR 0.55 vs L/L, p=0.033). 58 
Men with lower leisure, home or work PA and higher E2 were at greater risk of CVD death 59 
(eg. leisure L/H HR 1.60 vs L/L, p=0.039). 60 
 3 
Conclusions 61 
Considering T, DHT and E2 in the context of PA better informs consideration of 62 
cardiovascular risk. A 2x2 factorial RCT assessing PA and androgens would illuminate the 63 
scope for preventing CVD in men. 64 
 4 
Introduction 65 
 66 
As men grow older, circulating testosterone (T) concentrations decrease (1) while incidence of 67 
cardiovascular disease (CVD) increases.(2) Overweight older men have lower T levels 68 
compared to normal weight men of the same age (3) and reduced T levels are associated with 69 
poorer health outcomes including higher rates of metabolic syndrome and all-cause 70 
mortality.(4,5) This has raised the question of whether reduced circulating T might be a 71 
modifiable risk factor for cardiometabolic ill-health in ageing men, with increasing interest 72 
and controversy regarding the possible role of pharmacological T treatment as a means of 73 
preserving vascular health.(6) 74 
 75 
Testosterone is the predominant androgen in men’s circulation and drives the regulation of 76 
sexual development, virilisation, bone mineral density and body composition.(7) It is 77 
converted by 5α-reductase into dihydrotestosterone (DHT), a more potent androgen and by 78 
aromatase into estradiol (E2), a ligand for estrogen receptors.(8) Lower T, DHT, and higher 79 
E2 have been associated with features of the metabolic syndrome.(9) Furthermore, higher T 80 
and DHT are independent predictors for reduced incidence of stroke (10) with higher DHT 81 
also associated with reduced ischaemic heart disease mortality.(11) However, one randomised 82 
controlled trial (RCT) was terminated early due to excess cardiovascular events in a group of 83 
older men with limited mobility being treated with T,(12) although similar RCTs have not 84 
reproduced these findings (13,14) nor do meta-analyses associate testosterone supplementation 85 
with increased cardiovascular risk.(15)  86 
 87 
Healthy lifestyle behaviours, including exercise, have been associated with higher circulating 88 
T in men aged 65+ years.(16) Of interest, the combination of T treatment and exercise training 89 
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improves upper and lower limb skeletal muscle strength and performance to a greater extent 90 
than exercise alone in young and middle-aged men.(17) One study reported that body 91 
composition improved in older men (66±5 years) following 12 months of T treatment, 92 
regardless of whether they were randomised to exercise or usual care.(18) Thus it remains 93 
unclear whether men who exercise more and have higher circulating androgens would have 94 
lower risk of metabolic syndrome or CVD events compared to those who exercise less and 95 
have lower circulating androgens. 96 
 97 
Our aim was to assess whether physical activity (PA) levels interact with sex hormone 98 
concentrations to influence cardiometabolic risk factors and disease. We tested the hypothesis 99 
that higher PA and higher circulating androgens are independently associated with more 100 
favourable cardiometabolic risk profiles and reduced incidence of CVD events in 101 
community-dwelling men. 102 
 103 
Methods 104 
Study population and sample 105 
Busselton is in the coastal region of Western Australia with a predominantly Anglo-Celtic 106 
population. The Busselton Health Survey (BHS) includes a series of cross-sectional surveys 107 
conducted from 1966 to 1987.(19) Surviving participants of these surveys were invited to a 108 
follow-up survey in 1994/95. A total of 2143 men participated and provided blood samples 109 
for analysis. The relevant Human Research Ethics Committees approved the study and all 110 
participating men provided written consent.  111 
 112 
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Survey measurement methods 113 
Methods used in the 1994/95 Busselton Health Survey have previously been described.(19) All 114 
men completed a comprehensive health and lifestyle questionnaire and underwent a physical 115 
assessment that included anthropometry (height, weight, waist circumference via 116 
standardised protocols) and blood pressure (systolic and diastolic via mercury 117 
sphygmomanometer after five minutes rest seated) and a fasting blood sample. Smoking, 118 
diabetes, medication use and hours of PA for exercise/leisure, at home and at work per usual 119 
week were obtained by questionnaire.(20) Participants were asked how many hours were spent 120 
engaging in moderate or vigorous activities in each of the three environments with examples 121 
given for each.  For each physical activity setting we calculated (hours/week of moderate 122 
intensity activities) + 2 × (hours/week of vigorous intensity activity). Body mass index (BMI) 123 
was calculated as weight (kg) divided by square of height (m). 124 
 125 
Laboratory assays 126 
Serum cholesterol, high-density lipoprotein (HDL) and triglycerides (TG) were assayed using 127 
a Hitachi 747 analyser (Roche Diagnostics, Castle Hill, NSW, Australia) and glucose using a 128 
hexokinase assay at time of survey. Serum was stored at -70°C and serum T, DHT and E2 129 
were measured from 200μl samples in 2013 using a single liquid chromatography-tandem 130 
mass spectrometry (LC-MS) run without derivatization using atmospheric pressure photo-131 
ionization for positive mode for androgens and negative mode for oestrogens, as previously 132 
described.(9,21) Between run imprecision for T was 8.6% at a 5.3 nmol/L and 7.9% at 26.9 133 
nmol/L. For DHT between run imprecision was 11.3% at 1.3 nmol/L and 9.1% at 5.3 nmol/L. 134 
For E2 between run imprecision was 14.5% at 73 pmol/L and 9.9% at 279 pmol/L.(9) LH was 135 
assayed using immunoassay (Abbott Architect, Abbott Diagnostics, Australia) with between 136 
run imprecision of 5.6% at 4.8 IU/L. SHBG was assayed using a solid-phase, two site 137 
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enzyme immunometric assay with chemiluminescent substrate (Immulite 2000XPi; Siemens 138 
Healthcare, Bayswater, Vic., Australia) with between-run imprecision of 3.4% at 39.4 nmol/l. 139 
Free T was calculated using empirical formulae, which provides closer concordance with 140 
measured free T compared with calculations based on equilibrium binding equations.(22)  141 
 142 
Definition of metabolic syndrome and prevalent cardiovascular disease 143 
The metabolic syndrome score was defined using five risk components (hypertension, 144 
hyperglycemia, hypertriglyceridemia, high density lipoprotein (HDL) cholesterol, waist 145 
circumference) according to the National Cholesterol Education Program Adult Treatment 146 
Panel III 2005 criteria.(23) Hypertension was defined as systolic blood pressure ≥130 mmHg, 147 
or diastolic blood pressure ≥85 mmHg or drug treatment for hypertension. Hyperglycemia 148 
was defined as fasting glucose ≥5.6 mmol/L. Hypertriglyceridemia was defined as 149 
triglycerides ≥1.7 mmol/L or receipt of fibrates or nicotinic acid. Low high density 150 
lipoprotein (HDL) cholesterol was defined as HDL ≤1.0 mmol/L. Central obesity was 151 
defined as waist circumference ≥102 cm. A participant was regarded as having metabolic 152 
syndrome if three or more criteria were met. History of CVD at the time of survey attendance 153 
in 1994/95 was defined as any hospital admission for CVD (ICD-9 390-459) in the 15-year 154 
period before the survey. 155 
 156 
Ascertainment of fatal and non-fatal cardiovascular events during follow-up  157 
Follow-up for hospital admissions and deaths were available until mid-2014, amounting to 20 158 
years of follow-up. Outcome events were ascertained from hospital admissions and death 159 
records. Hospital admission codes used the ICD-9/ICD-9-CM system up to mid-1999 and 160 
ICD10-AM thereafter. Deaths from CVD were ascertained based on deaths with underlying 161 
cause of death coded as diseases of the circulatory system (ICD-9 390-459; ICD-10 I00-99, 162 
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G45). Non-fatal CVD events were defined as a hospital admission with a principal diagnosis 163 
of coronary heart disease (ICD-9 410-414; ICD-10 I20-25), stroke (ICD-9 430-437; ICD-10 164 
I60-68, G45), congestive heart failure (ICD-9 428; ICD-10 I50) or peripheral arterial disease 165 
(ICD-9 440-448; ICD-10 I70-79).  166 
 167 
Statistical analysis  168 
Characteristics of the survey sample are expressed as mean (SD) and median (interquartile 169 
range) for continuous data, and N (%) for categorical data. Men were divided into four 170 
groups (1) high PA and high hormone (H/H), (2) low PA and high hormone (L/H), (3) high 171 
PA and low hormone (H/L) and (4) low PA and low hormone (L/L) based on using median 172 
splits to determine high/low. For frequencies of the four groups, see Supplementary Table 1. 173 
In the cross-sectional analyses linear regression was used to compare mean BMI and waist 174 
circumference (after adjustment for age) across the four groups. Logistic regression was used 175 
to compare the prevalence of metabolic syndrome (after adjustment for age) across the four 176 
groups. In the longitudinal follow-up analysis, Cox proportional hazards regression analysis 177 
was used to compare risk of fatal and non-fatal CVD events (after adjustment for age, 178 
prevalent CVD, smoking, waist circumference, cholesterol, HDL, lipids medication, diabetes, 179 
SBP and hypertension medication) across the four groups. PA*hormone interaction analyses 180 
were conducted using PA and hormones as continuous variables.  181 
 182 
Results 183 
Baseline characteristics of study population 184 
After restricting the cohort to men aged 20-79 years and excluding men who were taking 185 
androgens, anti-androgens, or had a history of orchidectomy or prostate cancer, or with 186 
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missing PA or hormone variables, 1649 men were included in the analysis. Baseline 187 
demographic, physical and biochemical data are shown in Table 1.  188 
 189 
TABLE 1 190 
 191 
Associations of physical activity and sex hormones with BMI 192 
There was an inverse association of higher PA and higher T with lower BMI (in the age-193 
adjusted model (Table 2). Men in the H/H group had significantly lower BMI than those in 194 
the L/L group, with intermediate results for L/H and H/L groups (e.g. leisure H/H 25.4 195 
p<0.001; L/H 25.8 p<0.001; H/L 27.1 p<0.001 vs L/L 27.9 kg/m2). There were no PA*T 196 
interactions (all p≥0.18) suggesting that higher PA and higher T are independently associated 197 
with lower BMI. There were similar results with DHT (e.g. leisure H/H 25.7 p<0.001; L/H 198 
26.1 p<0.001; H/L 26.8 p<0.003 vs L/L 27.5). There were no PA*DHT interactions (all 199 
p≥0.05). Higher PA and higher E2 were generally not associated with BMI (all group 200 
comparisons p>0.05 except leisure H/H vs L/L with p=0.04), and there were no PA*E2 201 
interactions (all p≥0.16).  202 
 203 
TABLE 2 204 
 205 
Associations of physical activity and sex hormones with waist circumference 206 
There was an inverse association of higher PA and higher T with waist circumference in the 207 
age-adjusted model (Table 3). Men in the H/H group had significantly smaller waist 208 
circumference than those in the L/L group, with intermediate results for L/H and H/L groups 209 
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(e.g. leisure H/H 89.2 p<0.001; L/H 90.9 p<0.001; H/L 94.8 p<0.001 vs L/L 97.2 cm). There 210 
were similar results with DHT (e.g. leisure H/H 90.3, p<0.001; L/H 92.0 p<0.001; H/L 93.9 211 
p=0.002 vs L/L 95.9 cm). Strong interactions were present for work PA*DHT (p=0.006) and 212 
total PA*DHT (p=0.001).  There was a greater difference in waist circumference between 213 
men with low DHT vs men with high DHT irrespective of PA. For higher work and total PA, 214 
waist circumference was significantly lower in men with low DHT but not in men with high 215 
DHT (see Supplementary Table 7). Men with higher leisure, home or total PA and higher E2 216 
had significantly smaller waist circumferences (e.g. leisure H/H 91.6, p<0.001 vs L/L 93.9 217 
cm). There were no PA interactions for T (all p≥0.26) or E2 (all p≥0.09).  218 
TABLE 3 219 
 220 
Associations of physical activity and sex hormones with metabolic syndrome 221 
For all settings of PA, men with higher PA and higher T had lowest (age adjusted) odds of 222 
metabolic syndrome (Table 4). There were intermediate results for the L/H and H/L groups  223 
(e.g. leisure H/H odds ratio 0.166 p<0.001; L/H 0.323 p<0.001; H/L 0.744 p=0.078 vs L/L 224 
1.00). There were no PA*T interactions (all p≥0.05). Similar results were seen for DHT (e.g. 225 
leisure H/H 0.255 p<0.001; L/H 0.475 p<0.001; H/L 0.823 p=0.270 vs L/L 1.00). There were 226 
no PA*DHT interactions (all p≥0.27). For leisure, home, work and total PA, men with higher 227 
PA and higher E2 had the lowest odds of metabolic syndrome (e.g. leisure H/H 0.507, 228 
p=0.001; L/H 1.013, p=0.945; H/L 0.910, p=0.624 vs L/L 1.00). There were significant 229 
interactions between E2 and leisure PA (p=0.027), total PA (p=0.037), and home PA 230 
(p=0.026), with little difference in odds of metabolic syndrome in men with higher vs lower 231 
PA in the presence of low E2.  232 
 233 
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TABLE 4 234 
 235 
Cross sectional analyses of PA and cFT, and PA and SHBG 236 
For outcomes of BMI, waist and metabolic syndrome, the results of PA and cFT, and PA and 237 
SHBG largely mirror those seen with (total) T (Supplementary Tables 2-4). 238 
 239 
SUPPLEMENTARY TABLES 2-4 240 
 241 
Associations of physical activity and sex hormones with incident CVD events 242 
In the fully-adjusted model, there were no differences in the hazard ratio for CVD events for 243 
PA and hormones and no PA*hormone interactions (Table 5).  244 
 245 
TABLE 5 246 
 247 
Associations of physical activity and sex hormones with CVD deaths 248 
In the fully-adjusted model, men with higher leisure, work or total PA and higher DHT had 249 
the lowest risk of CVD death (e.g. leisure hazard ratio H/H 0.55, p=0.033; L/H 0.81, 250 
p=0.346; H/L 0.73, p=0.243 vs L/L 1.00; Table 6). There were no PA*DHT interactions (all 251 
p≥0.461). Men with lower leisure, home, or work PA and higher E2 have an increased hazard 252 
ratio of CVD death (eg. Leisure L/H HR 1.60 vs L/L, p=0.039). There were no PA*E2 253 
interactions (all p≥0.22).  254 
 255 
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TABLE 6 256 
 257 
Longitudinal analyses of PA and cFT, and PA and SHBG 258 
For the outcome of CVD events and CVD deaths, there were no consistent associations 259 
observed (Supplementary Tables 5-6). Men with high work PA and high cFT had a lower 260 
hazard ratio for CVD death but this was not seen for men with high leisure, home or total PA 261 
and high cFT (Supplementary Table 6). Men with high work or total PA and low SHBG had 262 
a lower hazard ratio for CVD death but this was not seen for men with high leisure or home 263 
PA and low SHBG (Supplementary Table 6). 264 
 265 
SUPPLEMENTARY TABLES 5-6 266 
 267 
Discussion 268 
Higher PA and higher T or DHT were associated with lower BMI, waist circumference and 269 
odds of metabolic syndrome. There was an interaction between PA and DHT, with less 270 
difference in odds of metabolic syndrome attributable to PA in the presence of higher DHT. 271 
Men with higher leisure, work or total PA+higher DHT had the lowest risk of CVD death. 272 
Men with higher PA and higher E2 had the lowest odds of metabolic syndrome.  There was 273 
an interaction such that the difference attributable to higher PA was less in men with lower 274 
E2. Men with lower levels of leisure, home or work PA and higher E2 had the highest hazard 275 
ratio for CVD death. There were no PA*hormone interactions for the longitudinal outcomes. 276 
 277 
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Previous epidemiological studies have assessed associations of either PA or hormone levels 278 
(3,9-11,16,20,24-30) with outcomes related to cardiometabolic health, but not analyzed for 279 
interactions between the two. Some studies have adjusted for PA when examining hormones 280 
vs cardiometabolic outcomes. Tivesten et al. reported low serum T and E2 increased risk of 281 
mortality in a population of 3014 men,(24) when adjusted for by age, BMI, smoking and PA 282 
but the role of PA alone was not assessed. Similarly, a 2014 meta-analysis demonstrated men 283 
with low total T were more likely to have prevalent metabolic syndrome compared to men 284 
with high total T (4) and adjustment for lifestyle factors (smoking status, alcohol consumption, 285 
and PA) was reported to not materially change the odds ratio but again the role of PA in its 286 
own right was not evaluated. These approaches have left unanswered the question whether, 287 
and to what extent, higher levels of PA and higher circulating androgens might be 288 
independently or additively associated with lower CVD risk.  289 
 290 
We found that men with higher PA levels and higher levels of T had the lowest BMI, waist 291 
circumference and risk of metabolic system. Interestingly, this did not translate to any 292 
reduction in risk of CVD events or CVD mortality. Several epidemiological studies have 293 
reported associations of low T with poorer CVD-related outcomes in men (10,24) while others 294 
have reported negative or neutral results.(30-32) Low T concentrations have been associated 295 
with increased risk of mortality in the European Male Ageing Study (EMAS).(27) However, in 296 
older men, an optimal or mid-range T is the best predictor of longevity.(11) In this cohort of 297 
men, T appears to have less predictive utility for longitudinal CVD-related outcomes 298 
compared with DHT. 299 
 300 
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Men with higher PA and higher DHT had a lower BMI, waist circumference and risk of 301 
metabolic syndrome than men who had lower PA levels and/or lower DHT levels. There was 302 
an interaction between PA and DHT with respect to waist circumference. As a group men 303 
with high DHT had lower waist circumference compared to men with low DHT, and the 304 
relationship of higher PA with lower waist circumference was strong (and significant) in men 305 
with low DHT and weak (and non-significant) in men with high DHT. Men with higher 306 
leisure, work or total PA and higher DHT also had the lowest risk of CVD mortality. There 307 
were no interactions between PA and DHT for this longitudinal outcome. This is concordant 308 
with our previous finding that older men with higher DHT have a lower mortality from 309 
ischaemic heart disease.(11) Furthermore, in the Cardiovascular Health Study there was a 310 
curvilinear association between DHT and CVD but an inverse association with all-cause 311 
mortality.(28) Those studies did not examine whether PA and T or DHT might interact to 312 
influence outcomes. Our results from men across a range of ages extend these observations 313 
demonstrating additive or independent associations of higher PA and higher DHT with lower 314 
CVD mortality, highlighting the value of DHT as an informative biomarker. 315 
 316 
Men who had higher leisure PA levels had a significantly lower BMI and waist 317 
circumference than men who exercised less, independent of E2 levels. However men with 318 
higher (leisure, home, work or total) PA levels and higher E2 had significantly reduced risk 319 
of metabolic syndrome compared to men with high E2 and low PA. The difference associated 320 
with PA was not as apparent in men with low E2.  Low leisure, home or work PA coupled 321 
with a high E2 level was predictive of increased CVD mortality. Previous epidemiological 322 
studies have not associated E2 with mortality from ischaemic heart disease or all-cause 323 
mortality.(11,26) However, other studies have reported an inverse association with E2 and CVD 324 
mortality (29) and all-cause mortality.(24,30) Results from the present study indicate that in men 325 
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with higher E2 levels, having higher rather than lower PA levels are associated with more 326 
favourable cross-sectional and longitudinal outcomes.  327 
 328 
We acknowledge several limitations of the present study. As this was an observational study 329 
it precludes the ability to infer causality. Physical activity data were obtained via 330 
questionnaires susceptible to recall bias. Both PA and hormones were assessed at baseline 331 
and we did not include serial measures of these variables over time. We dichotomized 332 
variables for ease of presentation and interpretation of results. However we also analysed 333 
interactions with PA and hormones as continuous variables. While there is the possibility of 334 
false-positive findings occurring by chance due to multiple comparisons, it is reassuring that 335 
we have found consistently significant results in specific PA and hormone groups across the 336 
different categories of PA. As men in the analysis had attended previous surveys, a ‘healthy 337 
survivor’ effect may be present. Lastly, the BHS men are predominantly Anglo-Celtic so 338 
results may not apply to men from other ethnic backgrounds or to women.  339 
 340 
The androgen receptor (AR) gene contains a CAG repeat sequence, and receptors with longer 341 
CAG repeat sequences exhibit impaired transcriptional activity. (33) In men with type 2 342 
diabetes, the AR CAG repeat was positively associated with waist circumference and BMI 343 
independently of testosterone and estradiol concentrations. (34) Conversely in a different study 344 
men with shorter CAG repeats had higher systolic blood pressure, and lower HDL 345 
cholesterol. (35) As we did not measure AR CAG repeat length in our cohort we are unable to 346 
comment on the role of AR sensitivity, or AR-independent mechanisms by which 347 
testosterone might modulate cardiovascular risk. 348 
 349 
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Strengths of our study include the large cohort of community-dwelling men with detailed 350 
baseline characterization. The different classifications of PA (leisure, home, work, total) 351 
allowed us to investigate to what extent each type influenced cardiometabolic health, and 352 
whether results were consistent across categories. In the majority of our examples, we have 353 
used leisure PA as is it has been consistently informative in our analyses and is also 354 
associated with longer life expectancy.(36) Serum T, DHT and E2 were assayed using LC-MS. 355 
We analyzed associations of PA and hormones with cardiometabolic outcomes, specifically 356 
evaluating for PA*hormone interactions. The long period of follow-up (20-years) facilitated 357 
assessment of outcome events.  358 
 359 
Previous interventional studies have assessed the effect of T treatment on cardiometabolic 360 
outcomes in men with low-normal baseline T and metabolic syndrome and/or Type 2 361 
diabetes mellitus (T2DM).(31,32) Jones et al. reported improvements in insulin resistance, 362 
cholesterol and sexual health in men following six months of T treatment.(31) Similarly, 363 
following 30 weeks of T administration, Kalinchenko et al. reported improvements in 364 
features of the metabolic syndrome and inflammatory markers.(32) However, these studies 365 
used background lifestyle interventions, generally encouraging uptake of healthy lifestyle 366 
behaviors rather than testing for additive effects of exercise and T. With a structured 10-week 367 
exercise intervention, Bhasin et al. reported supraphysiologic doses of T were additive to the 368 
increases in strength and muscle size in healthy men.(17) In a cohort of 71 frail elderly men 369 
(mean age 78.2 ± 6.4yrs), the addition of T to 12-weeks of high-intensity resistance exercise 370 
led to greater muscle hypertrophy.(37) One study assessed the effect of T treatment in 371 
apparently healthy older men following 12-months of strength training (18) where findings 372 
were generally consistent with previous studies indicating that T+PA improved body 373 
composition measures more so than either intervention alone. However, the aforementioned 374 
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studies were designed to detect differences in body composition and muscle strength and 375 
performance, rather than cardiometabolic outcomes. Of note, a recent meta-analysis limited 376 
to rigorous double-blind placebo-controlled RCTs of testosterone in men with metabolic 377 
syndrome or diabetes showed a marginal improvement in indices of insulin sensitivity, but no 378 
evidence of better glycemic control in men with relatively well controlled diabetes, or 379 
improvement in the Aging Male Symptom score.(38) 380 
 381 
Our findings are consistent with independent and additive associations of PA and T on 382 
indices of body composition, with no evidence of interaction to suggest that one might 383 
modify the association of the other. Men with higher PA and higher DHT had lower BMI, 384 
waist circumference and metabolic syndrome, with an interaction between PA and DHT on 385 
waist circumference. Unlike the longitudinal analyses of PA and T, which showed no 386 
associations with CVD mortality, men with higher PA and DHT levels had lower risk of 387 
CVD mortality. Of note, men with high E2 and high PA were less likely to have metabolic 388 
syndrome, but those with high E2 and low PA had increased risk of CVD death. Overall, our 389 
results suggest that high PA and androgens, particularly DHT, predict more favourable 390 
outcomes. Conversely, high E2 and low PA predict less favourable outcomes. Key questions 391 
remain as to the direction of causation, and whether manipulation of both PA and hormone 392 
levels could modify cardiovascular risk. 393 
 394 
A 2x2 factorial RCT in men with low-normal baseline T would be needed to clarify whether 395 
an exercise intervention combined with T would reduce cardiovascular and mortality risk 396 
more than either alone, or neither.  Analyses of on-treatment concentrations of the T 397 
metabolites, DHT and E2, in relation to the study outcomes would also provide greater 398 
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understanding of the potential contribution of each hormone in the presence of PA. However, 399 
benefits of such interventions need to be weighed carefully against the potential risks in light 400 
of a recent systematic review demonstrating a possible increased risk of CV events during the 401 
first 12 months for men ≥65 years receiving T supplementation.(15) 402 
 403 
Conclusions 404 
The most favourable combination of PA and hormone variables appears to be higher T and 405 
DHT with greater PA. Conversely men with higher E2 levels have less favourable outcomes 406 
in the presence of lower PA. Causality remains to be proven by appropriately designed 407 
randomised controlled trials. 408 
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